Epilepsy - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Epilepsy Emerging Therapy and TPP Insights

Thelansis's "Epilepsy Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Epilepsy Overview

Epilepsy is a chronic neurological condition marked by recurrent seizures, and while a broad set of anti-seizure medications has long formed the backbone of treatment, a persistent share of patients continue to experience seizures despite multiple drug options, a category known as drug-resistant epilepsy that remains one of neurology's most durable unmet needs. For these patients, care has traditionally escalated toward surgical removal of the seizure-generating brain region or implantable neuromodulation devices that interrupt abnormal electrical activity, alongside dietary approaches in select cases. The innovation frontier is now shifting toward precision, mechanism-differentiated approaches: gene-targeted strategies for specific genetic epilepsy syndromes, novel small molecules engineered to avoid the tolerance that limits existing drugs, and early cell-based therapies aimed at restoring inhibitory brain circuitry where surgery cannot easily reach. For stakeholders, epilepsy illustrates a mature category where broad-spectrum treatment has plateaued, opening space for precision-guided and device-based innovation to reach patients still left without adequate seizure control.

Key Highlight

• In Germany, total prevalent epilepsy cases are projected to increase from 911,531 in 2025 to 998,705 by 2035.
• Epilepsy remains one of the most common chronic neurological disorders worldwide.
• While many patients achieve seizure control, a significant proportion remain drug-resistant.
• Growing focus on personalized treatment and advanced neuromodulation technologies.

Market Overview

• The France epilepsy market is projected to grow from $819M in 2025 to $1.07B by 2035.
• Market growth is supported by:
• Increased utilization of newer anti-seizure medications
• Growing adoption of adjunctive therapies for refractory epilepsy
• Future growth will depend on innovative therapies targeting drug-resistant populations.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Ono Pharmaceutical Co., Ltd.
• Supernus Pharmaceuticals, Inc.
• Shanghai UniXell Biotechnology Co., Ltd.
• NeuroPro Therapeutics, Inc.
• Neurelis, Inc.
• UCB Biopharma SRL
• Janssen Research & Development, LLC
• UCB Pharma SA
• Eisai Korea Inc.
• Nova Pneuma Inc.
• Shanghai Zhimeng Biopharma, Inc.
• Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• Biohaven Therapeutics Ltd.
• Rapport Therapeutics Inc.
• SK Life Science, Inc.
• Suninflam Inc.
• Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
• NeuroPace
• Xenon Pharmaceuticals Inc.
• Bright Minds Biosciences Pty Ltd.
• UCB Japan Co. Ltd.